Rescop Opens New Offices in the United Kingdom and Australia
Rescop announced today the opening of their offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners), an international life sciences service and solution provider, announced today the opening of their offices in the U.K. and Australia. Following the opening of offices in Belgium and the USA in 2013, the opening of these new offices is a next step as part of the internationalization strategy of Rescop, in order to serve their clients globally.
Piet Vervoort, Rescop’s Managing Director, said:
“We’re excited to expand our activities in the U.K. and Australia. The move was required to accommodate both our current and future growth in E.U. and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
Since its founding in 2005 by Piet Vervoort and Björn Aalbers, Rescop, with its headquarters in Den Bosch, has grown to 8 offices globally.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
